2023 World Conference on Lung Cancer (Posters)-EP12.01. Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam

EP12.01. Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the efficacy and tolerability of afatinib, a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in Vietnamese patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) in a real-world setting. The study included 100 patients who were treated with first-line afatinib at a single center in Ho Chi Minh City Oncology Hospital between January 2018 and June 2021.<br /><br />The results showed that first-line afatinib treatment in Vietnamese patients with EGFR-mutated NSCLC had a median time on treatment (TOT) of 17.5 months, with the TOT being similar across different mutation types and baseline brain metastasis status. The objective response rate (ORR) was 60% and the disease control rate (DCR) was 100%, indicating a high efficacy of afatinib in these patients. The median overall survival (OS) was not yet mature, but the 1-year and 2-year OS rates were 87% and 72%, respectively.<br /><br />In terms of tolerability, the most common side effects of afatinib treatment in these Vietnamese patients were rash/acne, diarrhea, paronychia, and stomatitis. The incidence of grade 3 side effects was low, with only 5% of patients experiencing such side effects.<br /><br />Overall, this real-world experience suggests that first-line afatinib treatment is effective and well-tolerated in Vietnamese patients with EGFR mutation-positive NSCLC. These findings provide valuable insights into the use of afatinib in a real-world setting and contribute to the limited data available on the efficacy and tolerability of EGFR TKIs, including afatinib, in Vietnamese patients.

Asset Subtitle

Chau Pham

Meta Tag

Speaker Chau Pham

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

afatinib

epidermal growth factor receptor tyrosine kinase inhibitor

EGFR-TKI

Vietnamese patients

EGFR mutation-positive non-small cell lung cancer

real-world setting

first-line treatment

time on treatment

objective response rate

disease control rate